By Colin Kellaher

BioCryst Pharmaceuticals has won U.S. Food and Drug Administration priority review for an application seeking expanded approval of its Orladeyo hereditary-angioedema drug for children ages 2 through 11.

BioCryst on Wednesday said an FDA green light would make Orladeyo the first targeted oral prophylactic therapy for children under the age of 12 with hereditary angioedema, a genetic disorder characterized by recurrent episodes of severe swelling.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. BioCryst said the agency set a target action date of Sept. 12 for the application.

The FDA approved Orladeyo in December 2020 to prevent hereditary-angioedema attacks in patients 12 and older.

BioCryst, a Durham, NC., biotechnology company, earlier this month raised its 2025 global Orladeyo revenue forecast to $580 million to $600 million from a prior range of $535 million to $550 million.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

May 14, 2025 07:33 ET (11:33 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.